IFIH1 and clinically amyopathic dermatomyositis: The anti-CADM140 antibody, also known as anti-MDA5 targeting melanoma differentiation associated gene 5, is found in 20–30% of patients with DM and characterises the clinical subset “clinically amyopathic DM” (CADM).